What is the SMS Pharmaceuticals PE ratio today?
SMS Pharmaceuticals' PE ratio is 44.3 at the 29 October 2026 close (₹485.80 a share): a market capitalisation of ₹4,550 crore divided by consolidated net profit of ₹103 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹102 crore) it is 44.6.
What is the SMS Pharmaceuticals PB ratio (price to book value)?
SMS Pharmaceuticals' price-to-book (PB) ratio is 5.79 at the 29 October 2026 close: a market capitalisation of ₹4,550 crore divided by shareholders' equity (book value) of ₹786 crore on 31 March 2026. That is a book value of ₹83.91 per share against a share price of ₹485.80.
What is the SMS Pharmaceuticals book value per share?
SMS Pharmaceuticals' book value per share was ₹83.91 on 31 March 2026: shareholders' equity of ₹786 crore divided by the 9.37 crore shares in issue, up 16.3% from ₹72.15 a year earlier. The share price at the 29 October 2026 close was ₹485.80.
What is the SMS Pharmaceuticals market cap?
SMS Pharmaceuticals' market capitalisation was ₹4,550 crore at the 29 October 2026 close: 9.37 crore shares at ₹485.80 each.
Is SMS Pharmaceuticals debt free?
No. SMS Pharmaceuticals had borrowings of ₹365 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.46. Its cash and current investments were ₹46.1 crore, so its net debt was ₹319 crore.
What is the SMS Pharmaceuticals dividend in 2026 and its record date?
In 2026, SMS Pharmaceuticals has declared one dividend: ₹0.40 with record date 22 September 2026.
What is the SMS Pharmaceuticals debt to equity ratio?
SMS Pharmaceuticals' debt-to-equity ratio was 0.46 on 31 March 2026: borrowings of ₹365 crore against total equity of ₹786 crore. A year earlier, on 31 March 2025, it was 0.49.
What is the SMS Pharmaceuticals net worth?
SMS Pharmaceuticals' net worth — shareholders' equity in its consolidated balance sheet — was ₹786 crore on 31 March 2026, up 22.9% from ₹640 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹4,550 crore at the 29 October 2026 close.
What is the SMS Pharmaceuticals promoter holding?
Promoters held 68.07% of SMS Pharmaceuticals on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the SMS Pharmaceuticals ROE and ROCE?
In FY26, SMS Pharmaceuticals' return on equity (ROE) was 14.3% and its return on capital employed (ROCE) was 14.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.7% and ROCE 13.7%.
What is the SMS Pharmaceuticals dividend yield?
SMS Pharmaceuticals' dividend yield is 0.08% at the 29 October 2026 close: dividends of ₹0.40 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹485.80. They were ₹0.40 on 22 September 2026.
What is the SMS Pharmaceuticals shareholding pattern?
On 30 September 2026, SMS Pharmaceuticals' shares were held by promoters 68.07%, foreign portfolio investors (FII/FPI) 1.18%, domestic institutions (DII) 0.20% (including mutual funds at 0.00%) and retail and other non-institutional investors 30.56%. Over the year, FII holding was up 0.90 percentage points from 0.28% and DII holding was down 2.68 percentage points from 2.88%.
What is the SMS Pharmaceuticals EPS?
SMS Pharmaceuticals' basic earnings per share (EPS) were ₹11.15 in FY26, against ₹8.16 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹11.24.
What is the SMS Pharmaceuticals revenue and profit in FY26?
In FY26 (April 2025–March 2026), SMS Pharmaceuticals' consolidated net profit was ₹102 crore, up 48.8% from ₹68.6 crore in FY25, on revenue from operations of ₹887 crore (up 13.3%).
When are the SMS Pharmaceuticals next results?
SMS Pharmaceuticals will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.
What is the SMS Pharmaceuticals free cash flow?
In FY26, SMS Pharmaceuticals generated ₹59.2 crore of cash from operations and spent ₹131 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹71.3 crore. In FY25 it was −₹41.7 crore.
What are the SMS Pharmaceuticals latest quarterly results?
SMS Pharmaceuticals' latest results are for Q1 FY27 (April–June 2026), filed on 31 July 2026: consolidated net profit ₹20.9 crore, up 2.0% from ₹20.5 crore in Q1 FY26; revenue from operations ₹207 crore, up 5.6% year on year.
SMS Pharmaceuticals vs Ind-Swift Laboratories: how do they compare?
In FY26, SMS Pharmaceuticals earned net profit of ₹102 crore on revenue of ₹887 crore, against ₹41.4 crore on ₹641 crore for Ind-Swift Laboratories. SMS Pharmaceuticals' operating margin was 14.8% (Ind-Swift Laboratories 2.3%) and its return on equity 14.3% (Ind-Swift Laboratories 3.2%). At the 29 October 2026 close, SMS Pharmaceuticals' market capitalisation was ₹4,550 crore against ₹3,564 crore for Ind-Swift Laboratories, and its PE ratio on FY26 profit 44.6 against 86.0.
How does SMS Pharmaceuticals compare with its peers?
On FY26 consolidated figures, against Ind-Swift Laboratories, Solara Active Pharma Sciences and Dishman Carbogen Amcis: SMS Pharmaceuticals' operating margin of 14.8% is the highest of the four (Ind-Swift Laboratories 2.3%, Solara Active Pharma Sciences 6.4%, Dishman Carbogen Amcis 7.7%; peer average 5.5%); its return on equity of 14.3% is the highest of the four (Ind-Swift Laboratories 3.2%, Solara Active Pharma Sciences −0.6%, Dishman Carbogen Amcis 1.6%; peer average 1.4%); its revenue growth over three years of 19.3% a year is the highest of the four (Ind-Swift Laboratories −19.0% a year, Solara Active Pharma Sciences −1.8% a year, Dishman Carbogen Amcis 6.7% a year; peer average −4.7% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
